AU2017277497B2 - Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells - Google Patents

Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells Download PDF

Info

Publication number
AU2017277497B2
AU2017277497B2 AU2017277497A AU2017277497A AU2017277497B2 AU 2017277497 B2 AU2017277497 B2 AU 2017277497B2 AU 2017277497 A AU2017277497 A AU 2017277497A AU 2017277497 A AU2017277497 A AU 2017277497A AU 2017277497 B2 AU2017277497 B2 AU 2017277497B2
Authority
AU
Australia
Prior art keywords
sbt
oil
dha
composition
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017277497A
Other languages
English (en)
Other versions
AU2017277497A1 (en
Inventor
Mansoor M. Amiji
Galina Ivanovna BOTCHKINA
James E. Egan
Iwao Ojima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Targagenix Inc
Northeastern University Boston
Research Foundation of the State University of New York
Original Assignee
Northeastern University China
Targagenix Inc
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northeastern University China, Targagenix Inc, Research Foundation of the State University of New York filed Critical Northeastern University China
Publication of AU2017277497A1 publication Critical patent/AU2017277497A1/en
Application granted granted Critical
Publication of AU2017277497B2 publication Critical patent/AU2017277497B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017277497A 2016-06-07 2017-06-07 Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells Active AU2017277497B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662346755P 2016-06-07 2016-06-07
US62/346,755 2016-06-07
PCT/US2017/036330 WO2017214260A1 (en) 2016-06-07 2017-06-07 Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells

Publications (2)

Publication Number Publication Date
AU2017277497A1 AU2017277497A1 (en) 2018-12-20
AU2017277497B2 true AU2017277497B2 (en) 2023-05-04

Family

ID=60578981

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017277497A Active AU2017277497B2 (en) 2016-06-07 2017-06-07 Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells

Country Status (9)

Country Link
US (3) US10206875B2 (enExample)
EP (1) EP3463299A4 (enExample)
JP (1) JP7518604B2 (enExample)
CN (2) CN116019768A (enExample)
AU (1) AU2017277497B2 (enExample)
CA (1) CA3026412A1 (enExample)
IL (1) IL263504A (enExample)
MX (1) MX2018015112A (enExample)
WO (1) WO2017214260A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7518604B2 (ja) * 2016-06-07 2024-07-18 タルガジェニックス，インコーポレイテッド タキソイド薬物のナノエマルション組成物、並びに標的癌細胞及び癌幹細胞に対するその使用方法
CA3121615A1 (en) * 2017-12-20 2019-06-27 Targagenix, Inc. Combination taxoid nanoemulsion with immunotherapy in cancer
JP7610208B2 (ja) * 2019-03-22 2025-01-08 インテグレイテッド ナノセラピューティクス インコーポレイテッド 足場部分から調製した脂質結合体
CN114599394A (zh) * 2019-10-25 2022-06-07 安进公司 用于在低蛋白浓度下使蛋白损失最小化的组合物和方法
CA3157484A1 (en) * 2019-11-05 2021-05-14 Ulagaraj Selvaraj Nanoparticles comprising prodrugs stabilized by albumin for treatment of cancer and other diseases
CN111004195B (zh) * 2019-12-03 2022-01-28 沈阳药科大学 卡巴他赛弱碱性衍生物及其制剂
CN114317398B (zh) * 2020-09-27 2024-03-01 中国科学院分子细胞科学卓越创新中心 Gli1和EpCAM基因共同标记的肝祖细胞群及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070088076A1 (en) * 2003-10-30 2007-04-19 Iwao Ojima Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
US20140105829A1 (en) * 2012-10-15 2014-04-17 Nemucore Medical Innovations, Inc. Therapeutic nanoemulsion formulation for the targeted delivery of docetaxel and methods of making and using the same
WO2015193380A2 (en) * 2014-06-19 2015-12-23 Solural Pharma ApS Solid oral dosage form of lipophilic compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
US20070148194A1 (en) * 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
EP2317978A2 (en) * 2008-07-23 2011-05-11 Bharat Serums And Vaccines Ltd. Stable injectable oil-in-water docetaxel nanoemulsion
US20100021471A1 (en) * 2008-07-25 2010-01-28 Brookhaven Science Associates, Llc Carbon nanotube-based drug delivery systems and methods of making same
JP6634034B2 (ja) * 2014-06-25 2020-01-22 シネルジア・バイオ・サイエンシーズ・プライベイト・リミテッドＳｙｎｅｒｇｉａ Ｂｉｏ Ｓｃｉｅｎｃｅｓ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 医薬水中油型ナノエマルジョン
JP7518604B2 (ja) * 2016-06-07 2024-07-18 タルガジェニックス，インコーポレイテッド タキソイド薬物のナノエマルション組成物、並びに標的癌細胞及び癌幹細胞に対するその使用方法
CA3121615A1 (en) * 2017-12-20 2019-06-27 Targagenix, Inc. Combination taxoid nanoemulsion with immunotherapy in cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070088076A1 (en) * 2003-10-30 2007-04-19 Iwao Ojima Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
US20140105829A1 (en) * 2012-10-15 2014-04-17 Nemucore Medical Innovations, Inc. Therapeutic nanoemulsion formulation for the targeted delivery of docetaxel and methods of making and using the same
WO2015193380A2 (en) * 2014-06-19 2015-12-23 Solural Pharma ApS Solid oral dosage form of lipophilic compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KUNZNETSOVA, L. et al., 'Syntheses and evaluation of novel fatty acid-second-generation taxoid conjugates as promising anticancer agents', Bioorg. Med. Chem. Lett. 2006, vol. 16, issue 4, pages 974-977. *
LUNDBERG B.B; RISOVIC V; RAMASWAMY M; WASAN K.M: "A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 86, no. 1, 23 November 2002 (2002-11-23), AMSTERDAM, NL , pages 93 - 100, XP029376949, ISSN: 0168-3659, DOI: 10.1016/S0168-3659(02)00323-1 *
PING MA: "Paclitaxel Nano-Delivery Systems: A Comprehensive Review", JOURNAL OF NANOMEDICINE & NANOTECHNOLOGY, vol. 04, no. 02, 1 January 2013 (2013-01-01), XP055201444, DOI: 10.4172/2157-7439.1000164 *
SEITZ JOSHUA AND OJIMA IWAO: "Drug Conjugates with Polyunsaturated Fatty Acids", DRUG DELIVERY IN ONCOLOGY, vol. Chapter41, JPN6021016857, 2012, pages 1323 - 1357, XP055456833, ISSN: 0004500951 *

Also Published As

Publication number Publication date
EP3463299A1 (en) 2019-04-10
WO2017214260A1 (en) 2017-12-14
CN109562065A (zh) 2019-04-02
JP7518604B2 (ja) 2024-07-18
MX2018015112A (es) 2019-09-09
CN116019768A (zh) 2023-04-28
US20180028442A1 (en) 2018-02-01
CA3026412A1 (en) 2017-12-14
AU2017277497A1 (en) 2018-12-20
NZ748915A (en) 2024-09-27
JP2019523226A (ja) 2019-08-22
US10206875B2 (en) 2019-02-19
EP3463299A4 (en) 2020-01-15
USRE50096E1 (en) 2024-08-27
US20250009658A1 (en) 2025-01-09
IL263504A (en) 2019-01-31

Similar Documents

Publication Publication Date Title
US20250009658A1 (en) Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells
Ahmad et al. Nanoemulsion formulation of a novel taxoid DHA-SBT-1214 inhibits prostate cancer stem cell-induced tumor growth
Ravar et al. Hyaluronic acid-coated liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation
Zhang et al. Localized delivery of curcumin into brain with polysorbate 80-modified cerasomes by ultrasound-targeted microbubble destruction for improved Parkinson's disease therapy
Zhao et al. Co-delivery of curcumin and paclitaxel by “core-shell” targeting amphiphilic copolymer to reverse resistance in the treatment of ovarian cancer
Biddlestone-Thorpe et al. Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents
Shen et al. Coating solid lipid nanoparticles with hyaluronic acid enhances antitumor activity against melanoma stem-like cells
Feng et al. Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment
Yi et al. Co-delivery of pirarubicin and paclitaxel by human serum albumin nanoparticles to enhance antitumor effect and reduce systemic toxicity in breast cancers
US9545382B2 (en) Nanoparticle formulations for delivering multiple therapeutic agents
US10143700B2 (en) Nanoparticle formulations for delivering multiple therapeutic agents
Xu et al. Enhancing the efficacy and safety of doxorubicin against hepatocellular carcinoma through a modular assembly approach: the combination of polymeric prodrug design, nanoparticle encapsulation, and cancer cell-specific drug targeting
Qu et al. Oral nanomedicine based on multicomponent microemulsions for drug-resistant breast cancer treatment
Guo et al. Transferrin-functionalized microemulsions coloaded with coix seed oil and tripterine deeply penetrate to improve cervical cancer therapy
US12186428B2 (en) Combination taxoid nanoemulsion with immunotherapy in cancer
Zhang et al. A nanoconfined loading strategy for highly efficient siRNA delivery and cancer therapy
Wohlfart et al. Treatment of glioblastoma with poly (isohexyl cyanoacrylate) nanoparticles
Kommineni et al. Stealth liposomal chemotherapeutic agent for triple negative breast cancer with improved pharmacokinetics
Rajendra et al. Fabrication and in vitro evaluation of silk fibroin-folic acid decorated paclitaxel and hydroxyurea nanostructured lipid carriers for targeting ovarian cancer cells: A double sword approach
Turkekul et al. Potent suppression of prostate cancer cell growth and eradication of cancer stem cells by CD44-targeted nanoliposome-quercetin nanoparticles
Wen et al. Functional exosomes modified with chitosan effectively alleviate anthracycline-induced cardiotoxicity
Brioschi et al. Solid lipid nanoparticles for brain tumors therapy: state of the art and novel challenges
KR101314579B1 (ko) 파크리탁셀이 선적된 고분자 나노입자 및 그 제조방법
Movahedi et al. PD-L1-Targeted Co-Delivery of Two Chemotherapeutics for Efficient Suppression of Skin Cancer Growth. Pharmaceutics 2022, 14, 1488
CN115887416A (zh) 治疗黑色素瘤的靶向纳米制剂及其载体和应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)